<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00464308</url>
  </required_header>
  <id_info>
    <org_study_id>CR006397</org_study_id>
    <nct_id>NCT00464308</nct_id>
  </id_info>
  <brief_title>A Study to Compare the Number of Patients With Gastro-Oesophageal Reflux Disease (GORD) Achieving Heartburn and Regurgitation Symptom Resolution After Treatment With Either Rabeprazole Sodium 20mg, Esomeprazole 20mg or Esomeprazole 40mg</brief_title>
  <official_title>The Rabeprazole and Esomeprazole Reflux Assessment Trial (TREAT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen-Cilag Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen-Cilag Pty Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare, the number of patients with heartburn and
      regurgitation symptom resolution after treatment with either rabeprazole 20 mg, esomeprazole
      20 mg or esomeprazole 40 mg.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed to be conducted in a realistic General Practice (GP) setting, enrolling
      typical Gastro-oesophageal Reflux Disease (GORD) patients that present for treatment, and for
      whom a Proton Pump Inhibitor (PPI) would normally be prescribed. The study will be conducted
      over a 4-week period on the basis that current GP standard practice is to treat the GORD
      patient for a period of 4-weeks prior to reassessment and further follow-up if required. This
      study is conducted in patients with GORD - associated heartburn (with or without
      regurgitation) at multiple GP centers, treatment is assigned based on chance (randomized),
      similar to the toss of a coin and neither doctor or patient knows which treatment they will
      receive (double-blinded). Following screening to determine eligibility, patients will be
      randomized to receive oral treatment with either, 20 mg rabeprazole, 20 mg esomeprazole or 40
      mg esomeprazole once daily for 4 weeks. This 4-week study encompasses 2 protocol-mandated
      visits (baseline on day 0 and final visit on day 28). It is hypothesized that rabeprazole 20
      mg will be no less effective than (non-inferior) esomeprazole 40 mg for the degree of GORD
      symptom resolution. Patients will take one tablet (rabeprazole 20 mg or placebo) and one
      capsule (esomeprazole 20 mg, esomeprazole 40 mg or placebo) each day for 28 days. The study
      medication will be taken once daily in the morning before breakfast, except the first dose,
      which will be taken during Visit 1.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Patients With Complete Resolution of Heartburn by Week 4</measure>
    <time_frame>week 4 of treatment</time_frame>
    <description>Complete resolution is the absence of symptoms for any 7 consecutive days within the 4 week period assessed by the PAGI-SYM scale. This likert scale describes a series of symptoms as follows: 0-None, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5 Very Severe.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Patients Achieving Complete Resolution of Regurgitation Symptoms at Week 4</measure>
    <time_frame>4 weeks</time_frame>
    <description>Complete resolution is the absence of symptoms for any 7 consecutive days within the 4 week period assessed by the PAGI-SYM scale. This likert scale describes various symptoms as follows: 0-none, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5-Very Severe.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Patients Achieving Satisfactory Resolution of Heartburn by Week 4</measure>
    <time_frame>4 weeks</time_frame>
    <description>Satisfactory resolution, which is achieved if, on any 7 consecutive days within the 4 week period, the severity of symptoms never exceeds 'mild' (symptoms must be absent, very mild, or mild) assessed by the PAGI-SYM scale. This likert scale describes various symptoms as follows: 0-none, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5-Very Severe.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Patients Achieving Satisfactory Resolution of Regurgitation Symptoms by Week 4</measure>
    <time_frame>4 weeks</time_frame>
    <description>Satisfactory resolution, which is achieved if, on any 7 consecutive days within the 4 week period, the severity of symptoms never exceeds 'mild' (symptoms must be absent, very mild, or mild)assessed by the PAGI-SYM scale. This likert scale describes a series of symptoms as follows: 0-None, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5 Very Severe.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Median Time to Complete Resolution of Heartburn Symptoms.</measure>
    <time_frame>week 4 of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Median Time to Complete Relief of Regurgitation Symptoms</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Mean Percentage of Participants With 24-hour Heartburn Symptom Free Periods</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1392</enrollment>
  <condition>Gastro-oesophageal Reflux</condition>
  <arm_group>
    <arm_group_label>001</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Esomeprazole 40mg once daily for 28days - 1 placebo tab/cap &amp; 1 active tab/cap daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>002</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Esomeprazole 20mg once daily for 28days - 1 placebo tab/cap &amp; 1 active tab/cap daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>003</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rabeprazole 20mg once daily for 28days - 1 placebo tab/cap &amp; 1 active tab/cap daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole</intervention_name>
    <description>20mg once daily for 28days - 1 placebo tab/cap &amp; 1 active tab/cap daily</description>
    <arm_group_label>002</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rabeprazole</intervention_name>
    <description>20mg once daily for 28days - 1 placebo tab/cap &amp; 1 active tab/cap daily</description>
    <arm_group_label>003</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole</intervention_name>
    <description>40mg once daily for 28days - 1 placebo tab/cap &amp; 1 active tab/cap daily</description>
    <arm_group_label>001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Heartburn (defined as a feeling of burning or pain, rising from the epigastrium or
             lower part of the chest up towards the neck) with or without regurgitation

          -  Patients must have had episodes of heartburn with or without regurgitation for 3
             months or longer, and for &gt;= 3 days in the 7 days prior to randomisation

          -  Able to understand and complete questionnaires, able to give written informed consent,
             and have access to a telephone

        Exclusion Criteria:

          -  Patients requiring endoscopy within 4 weeks of randomisation or with gastrointestinal
             symptoms that, in the opinion of the investigator, require further investigation prior
             to or coincident with initiation of PPI therapy which would include, but are not
             limited to, alarm symptoms such as unintentional weight loss, progressive difficulty
             swallowing (dysphagia), iron deficiency anaemia and epigastric mass

          -  Significant gastrointestinal obstruction, major gastric or oesophageal surgery
             (excluding appendectomy or cholecystectomy), oesophageal stricture or pyloric
             stenosis, extra-oesophageal manifestations of reflux disease

          -  Patients with Barrett's oesophagus (&gt;3cm), Zollinger-Ellison Syndrome, scleroderma,
             malignancy (other than non-melanoma skin cancers) present within the last 5 years,
             hypersensitivity to rabeprazole or esomeprazole or any PPI, or any other significant
             condition that, in the opinion of the investigator, could interfere with the patients
             participation or compliance in the study such as past or current history of alcohol or
             drug abuse, hepatic, renal, pulmonary, respiratory abnormalities, or who have
             participated in an investigational drug or investigational device study within 30 days
             prior to the baseline visit or who are expected to do so during the 4 week study
             period

          -  Female patients who are currently pregnant or breast feeding, or who, in the opinion
             of the investigator, may become pregnant throughout the study

          -  Use of histamine-2 receptor antagonists (H2RAs) within 7 days of randomisation,
             anticholinergics, cholinergics, spasmolytics, opiates, sucralfate, proton pump
             inhibitors (PPIs), prokinetics, antibiotics (in relation to H. pylori treatment) or
             bismuth compounds within 14 days of randomisation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen-Cilag Pty Ltd Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen-Cilag Pty Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Belconnen</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bondi Junction</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brookvale</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Browns Plains</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Campbelltown</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Campsie</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Caringbah</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Castle Hill</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlestown</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dapto</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Darlinghurst</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dubbo</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elizabeth</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fairfield</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hoppers Crossing</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ingleburn</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leichhardt</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maroubra</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melton</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mount Druitt</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oaklands Park</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Royal Park</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wentworthville</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wyoming</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2007</study_first_submitted>
  <study_first_submitted_qc>April 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2007</study_first_posted>
  <results_first_submitted>June 9, 2009</results_first_submitted>
  <results_first_submitted_qc>August 26, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 30, 2010</results_first_posted>
  <last_update_submitted>April 2, 2014</last_update_submitted>
  <last_update_submitted_qc>April 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastroesophageal Reflux</keyword>
  <keyword>Heartburn</keyword>
  <keyword>Proton pump inhibitor</keyword>
  <keyword>GORD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Rabeprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Rabeprazole 20 mg/Day</title>
          <description>Rabeprazole 20 mg once daily for 28 days - 1 placebo tablet/capsule plus 1 active tablet/capsule daily</description>
        </group>
        <group group_id="P2">
          <title>Esomeprazole 40 mg/Day</title>
          <description>Esomeprazole 40 mg once daily for 28 days - 1 placebo tablet/capsule plus 1 active tablet/capsule daily</description>
        </group>
        <group group_id="P3">
          <title>Esomeprazole 20 mg/Day</title>
          <description>Esomeprazole 20 mg once daily for 28 days - 1 placebo tablet/capsule plus 1 active tablet/capsule daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="464"/>
                <participants group_id="P2" count="469"/>
                <participants group_id="P3" count="459"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="395"/>
                <participants group_id="P2" count="406"/>
                <participants group_id="P3" count="400"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="63"/>
                <participants group_id="P3" count="59"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient discontinued and other reasons</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rabeprazole 20 mg/Day</title>
          <description>Rabeprazole 20 mg once daily for 28 days - 1 placebo tablet/capsule plus 1 active tablet/capsule daily</description>
        </group>
        <group group_id="B2">
          <title>Esomeprazole 40 mg/Day</title>
          <description>Esomeprazole 40 mg once daily for 28 days - 1 placebo tablet/capsule plus 1 active tablet/capsule daily</description>
        </group>
        <group group_id="B3">
          <title>Esomeprazole 20 mg/Day</title>
          <description>Esomeprazole 20 mg once daily for 28 days - 1 placebo tablet/capsule plus 1 active tablet/capsule daily</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="464"/>
            <count group_id="B2" value="469"/>
            <count group_id="B3" value="459"/>
            <count group_id="B4" value="1392"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.8" spread="14.8"/>
                    <measurement group_id="B2" value="48" spread="14.7"/>
                    <measurement group_id="B3" value="46.2" spread="14.8"/>
                    <measurement group_id="B4" value="46.7" spread="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="204"/>
                    <measurement group_id="B2" value="208"/>
                    <measurement group_id="B3" value="208"/>
                    <measurement group_id="B4" value="620"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="260"/>
                    <measurement group_id="B2" value="261"/>
                    <measurement group_id="B3" value="251"/>
                    <measurement group_id="B4" value="772"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="464"/>
                    <measurement group_id="B2" value="469"/>
                    <measurement group_id="B3" value="459"/>
                    <measurement group_id="B4" value="1392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Patients With Complete Resolution of Heartburn by Week 4</title>
        <description>Complete resolution is the absence of symptoms for any 7 consecutive days within the 4 week period assessed by the PAGI-SYM scale. This likert scale describes a series of symptoms as follows: 0-None, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5 Very Severe.</description>
        <time_frame>week 4 of treatment</time_frame>
        <population>The intent-to-treat (ITT) population was used for all efficacy analyses. The data were reanalysed using the compliance population (defined as all subjects who consumed at least 80% of study medication and who completed at least 80% of data recording).</population>
        <group_list>
          <group group_id="O1">
            <title>Rabeprazole 20 mg/Day</title>
            <description>Rabeprazole 20 mg once daily for 28 days - 1 placebo tablet/capsule plus 1 active tablet/capsule daily</description>
          </group>
          <group group_id="O2">
            <title>Esomeprazole 40 mg/Day</title>
            <description>Esomeprazole 40 mg once daily for 28 days - 1 placebo tablet/capsule plus 1 active tablet/capsule daily</description>
          </group>
          <group group_id="O3">
            <title>Esomeprazole 20 mg/Day</title>
            <description>Esomeprazole 20 mg once daily for 28 days - 1 placebo tablet/capsule plus 1 active tablet/capsule daily</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Patients With Complete Resolution of Heartburn by Week 4</title>
          <description>Complete resolution is the absence of symptoms for any 7 consecutive days within the 4 week period assessed by the PAGI-SYM scale. This likert scale describes a series of symptoms as follows: 0-None, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5 Very Severe.</description>
          <population>The intent-to-treat (ITT) population was used for all efficacy analyses. The data were reanalysed using the compliance population (defined as all subjects who consumed at least 80% of study medication and who completed at least 80% of data recording).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="464"/>
                <count group_id="O2" value="469"/>
                <count group_id="O3" value="459"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="272"/>
                    <measurement group_id="O2" value="302"/>
                    <measurement group_id="O3" value="278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Primary endpoints were assessed using non-inferiority tests. See below.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A sample size of 450 subjects per arm will give a 90% power (with a one-sided 95% confidence interval and a minimal clinically important difference of 9%) to demonstrate non-inferiority of rabeprazole 20mg to esomeprazole 40mg with respect to the number of patients with complete resolution of heartburn with or without regurgitation at week 4</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>Adjustment for multiple comparisons was not made. The a priori threshold for statistical significance was p&lt;0.05. Tests were 2-sided except for the non-inferiority test which was 1-sided.</p_value_desc>
            <method>Non-inferiority</method>
            <param_type>Proportion difference</param_type>
            <param_value>-0.11</param_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>Assumed that the true resolution rates in the rab20 and eso40 groups would be 30% (0.3). Non inferiority was considered proven if the lower confidence interval of the one sided 95% CI of P(rab20)-P(e40) was above -9%</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Median Time to Complete Resolution of Heartburn Symptoms.</title>
        <time_frame>week 4 of treatment</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Rabeprazole 20 mg/Day</title>
            <description>Rabeprazole 20 mg once daily for 28 days - 1 placebo tablet/capsule plus 1 active tablet/capsule daily</description>
          </group>
          <group group_id="O2">
            <title>Esomeprazole 40 mg/Day</title>
            <description>Esomeprazole 40 mg once daily for 28 days - 1 placebo tablet/capsule plus 1 active tablet/capsule daily</description>
          </group>
          <group group_id="O3">
            <title>Esomeprazole 20 mg/Day</title>
            <description>Esomeprazole 20 mg once daily for 28 days - 1 placebo tablet/capsule plus 1 active tablet/capsule daily</description>
          </group>
        </group_list>
        <measure>
          <title>The Median Time to Complete Resolution of Heartburn Symptoms.</title>
          <population>ITT population</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="464"/>
                <count group_id="O2" value="469"/>
                <count group_id="O3" value="459"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="9" upper_limit="15"/>
                    <measurement group_id="O2" value="9" lower_limit="7" upper_limit="10"/>
                    <measurement group_id="O3" value="12" lower_limit="10" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Median Time to Complete Relief of Regurgitation Symptoms</title>
        <time_frame>4 weeks</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Rabeprazole 20 mg/Day</title>
            <description>Rabeprazole 20 mg once daily for 28 days - 1 placebo tablet/capsule plus 1 active tablet/capsule daily</description>
          </group>
          <group group_id="O2">
            <title>Esomeprazole 40 mg/Day</title>
            <description>Esomeprazole 40 mg once daily for 28 days - 1 placebo tablet/capsule plus 1 active tablet/capsule daily</description>
          </group>
          <group group_id="O3">
            <title>Esomeprazole 20 mg/Day</title>
            <description>Esomeprazole 20 mg once daily for 28 days - 1 placebo tablet/capsule plus 1 active tablet/capsule daily</description>
          </group>
        </group_list>
        <measure>
          <title>The Median Time to Complete Relief of Regurgitation Symptoms</title>
          <population>ITT population</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="464"/>
                <count group_id="O2" value="469"/>
                <count group_id="O3" value="459"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="7" upper_limit="12"/>
                    <measurement group_id="O2" value="11" lower_limit="8" upper_limit="14"/>
                    <measurement group_id="O3" value="13" lower_limit="10" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Patients Achieving Complete Resolution of Regurgitation Symptoms at Week 4</title>
        <description>Complete resolution is the absence of symptoms for any 7 consecutive days within the 4 week period assessed by the PAGI-SYM scale. This likert scale describes various symptoms as follows: 0-none, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5-Very Severe.</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rabeprazole 20 mg/Day</title>
            <description>Rabeprazole 20 mg once daily for 28 days - 1 placebo tablet/capsule plus 1 active tablet/capsule daily</description>
          </group>
          <group group_id="O2">
            <title>Esomeprazole 40 mg/Day</title>
            <description>Esomeprazole 40 mg once daily for 28 days - 1 placebo tablet/capsule plus 1 active tablet/capsule daily</description>
          </group>
          <group group_id="O3">
            <title>Esomeprazole 20 mg/Day</title>
            <description>Esomeprazole 20 mg once daily for 28 days - 1 placebo tablet/capsule plus 1 active tablet/capsule daily</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Patients Achieving Complete Resolution of Regurgitation Symptoms at Week 4</title>
          <description>Complete resolution is the absence of symptoms for any 7 consecutive days within the 4 week period assessed by the PAGI-SYM scale. This likert scale describes various symptoms as follows: 0-none, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5-Very Severe.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="464"/>
                <count group_id="O2" value="469"/>
                <count group_id="O3" value="459"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="281"/>
                    <measurement group_id="O2" value="283"/>
                    <measurement group_id="O3" value="276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Primary endpoints were assessed using non-inferiority tests. See below.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The sample size calculation was based upon the number of patients acheiveing complete resolution of HEARTBURN. A sample size of 450 subjects per arm will give a 90% power (with a one-sided 95% confidence interval and a minimal clinically important difference of 9%) to demonstrate non-inferiority of rabeprazole 20mg to esomeprazole 40mg with respect to the number of patients with complete resolution of heartburn with or without regurgitation at week 4</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>All statistical tests were interpreted at the 5% significance level (2-tailed).</p_value_desc>
            <method>non-inferiority</method>
            <param_type>Proportion difference</param_type>
            <param_value>-0.051</param_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>Non inferiority was considered proven if the lower confidence interval of the one sided 95% CI of P(rab20)-P(e40) was above -9%</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Patients Achieving Satisfactory Resolution of Heartburn by Week 4</title>
        <description>Satisfactory resolution, which is achieved if, on any 7 consecutive days within the 4 week period, the severity of symptoms never exceeds ‘mild’ (symptoms must be absent, very mild, or mild) assessed by the PAGI-SYM scale. This likert scale describes various symptoms as follows: 0-none, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5-Very Severe.</description>
        <time_frame>4 weeks</time_frame>
        <population>Symptom scores 0=none, 1=very mild, 2=mild, 3=moderate, 4=severe, 5=very severe</population>
        <group_list>
          <group group_id="O1">
            <title>Rabeprazole 20 mg/Day</title>
            <description>Rabeprazole 20 mg once daily for 28 days - 1 placebo tablet/capsule plus 1 active tablet/capsule daily</description>
          </group>
          <group group_id="O2">
            <title>Esomeprazole 40 mg/Day</title>
            <description>Esomeprazole 40 mg once daily for 28 days - 1 placebo tablet/capsule plus 1 active tablet/capsule daily</description>
          </group>
          <group group_id="O3">
            <title>Esomeprazole 20 mg/Day</title>
            <description>Esomeprazole 20 mg once daily for 28 days - 1 placebo tablet/capsule plus 1 active tablet/capsule daily</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Patients Achieving Satisfactory Resolution of Heartburn by Week 4</title>
          <description>Satisfactory resolution, which is achieved if, on any 7 consecutive days within the 4 week period, the severity of symptoms never exceeds ‘mild’ (symptoms must be absent, very mild, or mild) assessed by the PAGI-SYM scale. This likert scale describes various symptoms as follows: 0-none, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5-Very Severe.</description>
          <population>Symptom scores 0=none, 1=very mild, 2=mild, 3=moderate, 4=severe, 5=very severe</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="464"/>
                <count group_id="O2" value="469"/>
                <count group_id="O3" value="459"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="405"/>
                    <measurement group_id="O2" value="418"/>
                    <measurement group_id="O3" value="414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Primary endpoints were assessed using non-inferiority tests. See below.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The sample size calculation was based upon the number of patients acheiveing complete resolution of HEARTBURN. A sample size of 450 subjects per arm will give a 90% power (with a one-sided 95% confidence interval and a minimal clinically important difference of 9%) to demonstrate non-inferiority of rabeprazole 20mg to esomeprazole 40mg with respect to the number of patients with complete resolution of heartburn with or without regurgitation at week 4</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>Adjustment for multiple comparisons was not made. The a priori threshold for statistical significance was p&lt;0.05. Tests were 2-sided except for the non-inferiority test which was 1-sided.</p_value_desc>
            <method>non-inferiority</method>
            <param_type>Proportion difference</param_type>
            <param_value>-0.053</param_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>Non inferiority was considered proven if the lower confidence interval of the one sided 95% CI of P(rab20)-P(e40) was above -9%</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Patients Achieving Satisfactory Resolution of Regurgitation Symptoms by Week 4</title>
        <description>Satisfactory resolution, which is achieved if, on any 7 consecutive days within the 4 week period, the severity of symptoms never exceeds ‘mild’ (symptoms must be absent, very mild, or mild)assessed by the PAGI-SYM scale. This likert scale describes a series of symptoms as follows: 0-None, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5 Very Severe.</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rabeprazole 20 mg/Day</title>
            <description>Rabeprazole 20 mg once daily for 28 days - 1 placebo tablet/capsule plus 1 active tablet/capsule daily</description>
          </group>
          <group group_id="O2">
            <title>Esomeprazole 40 mg/Day</title>
            <description>Esomeprazole 40 mg once daily for 28 days - 1 placebo tablet/capsule plus 1 active tablet/capsule daily</description>
          </group>
          <group group_id="O3">
            <title>Esomeprazole 20 mg/Day</title>
            <description>Esomeprazole 20 mg once daily for 28 days - 1 placebo tablet/capsule plus 1 active tablet/capsule daily</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Patients Achieving Satisfactory Resolution of Regurgitation Symptoms by Week 4</title>
          <description>Satisfactory resolution, which is achieved if, on any 7 consecutive days within the 4 week period, the severity of symptoms never exceeds ‘mild’ (symptoms must be absent, very mild, or mild)assessed by the PAGI-SYM scale. This likert scale describes a series of symptoms as follows: 0-None, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5 Very Severe.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="464"/>
                <count group_id="O2" value="469"/>
                <count group_id="O3" value="459"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="397"/>
                    <measurement group_id="O2" value="413"/>
                    <measurement group_id="O3" value="402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Primary endpoints were assessed using non-inferiority tests. See below.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The sample size calculation was based upon the number of patients acheiveing complete resolution of HEARTBURN. A sample size of 450 subjects per arm will give a 90% power (with a one-sided 95% confidence interval and a minimal clinically important difference of 9%) to demonstrate non-inferiority of rabeprazole 20mg to esomeprazole 40mg with respect to the number of patients with complete resolution of heartburn with or without regurgitation at week 4</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>Adjustment for multiple comparisons was not made. The a priori threshold for statistical significance was p&lt;0.05. Tests were 2-sided except for the non-inferiority test which was 1-sided.</p_value_desc>
            <method>non-inferiority</method>
            <param_type>Proportion difference</param_type>
            <param_value>-0.061</param_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>Non inferiority was considered proven if the lower confidence interval of the one sided 95% CI of P(rab20)-P(e40) was above -9%</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Mean Percentage of Participants With 24-hour Heartburn Symptom Free Periods</title>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rabeprazole 20 mg/Day</title>
            <description>Rabeprazole 20 mg once daily for 28 days - 1 placebo tablet/capsule plus 1 active tablet/capsule daily</description>
          </group>
          <group group_id="O2">
            <title>Esomeprazole 40 mg/Day</title>
            <description>Esomeprazole 40 mg once daily for 28 days - 1 placebo tablet/capsule plus 1 active tablet/capsule daily</description>
          </group>
          <group group_id="O3">
            <title>Esomeprazole 20 mg/Day</title>
            <description>Esomeprazole 20 mg once daily for 28 days - 1 placebo tablet/capsule plus 1 active tablet/capsule daily</description>
          </group>
        </group_list>
        <measure>
          <title>The Mean Percentage of Participants With 24-hour Heartburn Symptom Free Periods</title>
          <units>percent of participants</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="464"/>
                <count group_id="O2" value="469"/>
                <count group_id="O3" value="459"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.3" lower_limit="53.1" upper_limit="59.5"/>
                    <measurement group_id="O2" value="63.4" lower_limit="60.2" upper_limit="66.6"/>
                    <measurement group_id="O3" value="56.1" lower_limit="52.9" upper_limit="59.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Rabeprazole 20 mg/Day</title>
          <description>Rabeprazole 20 mg once daily for 28 days - 1 placebo tablet/capsule plus 1 active tablet/capsule daily</description>
        </group>
        <group group_id="E2">
          <title>Esomeprazole 40 mg/Day</title>
          <description>Esomeprazole 40 mg once daily for 28 days - 1 placebo tablet/capsule plus 1 active tablet/capsule daily</description>
        </group>
        <group group_id="E3">
          <title>Esomeprazole 20 mg/Day</title>
          <description>Esomeprazole 20 mg once daily for 28 days - 1 placebo tablet/capsule plus 1 active tablet/capsule daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="469"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="469"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>meniscal tear of right knee</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>multiple pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>alleged assault</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>perianal abscess drainage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="151" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="155" subjects_at_risk="469"/>
                <counts group_id="E3" subjects_affected="158" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal motility and defaecation cond</sub_title>
                <counts group_id="E1" events="26" subjects_affected="24" subjects_at_risk="464"/>
                <counts group_id="E2" events="32" subjects_affected="29" subjects_at_risk="469"/>
                <counts group_id="E3" events="40" subjects_affected="36" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Gastrointestinal signs and symptoms</sub_title>
                <counts group_id="E1" events="86" subjects_affected="63" subjects_at_risk="464"/>
                <counts group_id="E2" events="80" subjects_affected="67" subjects_at_risk="469"/>
                <counts group_id="E3" events="77" subjects_affected="54" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Salivary gland conditions</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="464"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="469"/>
                <counts group_id="E3" events="7" subjects_affected="4" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections - pathogen class unspecified</sub_title>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="464"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="469"/>
                <counts group_id="E3" events="29" subjects_affected="26" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Viral infectious disorders</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="464"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="469"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="464"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="469"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="464"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="469"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Muscle disorders</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="464"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="469"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders NEC</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="464"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="469"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="469"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headaches</sub_title>
                <counts group_id="E1" events="22" subjects_affected="19" subjects_at_risk="464"/>
                <counts group_id="E2" events="30" subjects_affected="24" subjects_at_risk="469"/>
                <counts group_id="E3" events="32" subjects_affected="31" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Neurological disorders NEC</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="464"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="469"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The MCID of 7.5% was amended to 9% to maintain power with smaller sample size.The proportion of patients without heartburn symptoms at baseline was not evenly distributed between treatment arms. This was a significant predictor of symptom resolution.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Executive Director, Medical &amp; Scientific Affairs</name_or_title>
      <organization>Janssen-Cilag Pty Ltd</organization>
      <phone>+61 2 9815 3219</phone>
      <email>mhandel@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

